PT2121011E - Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe - Google Patents
Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe Download PDFInfo
- Publication number
- PT2121011E PT2121011E PT78666328T PT07866632T PT2121011E PT 2121011 E PT2121011 E PT 2121011E PT 78666328 T PT78666328 T PT 78666328T PT 07866632 T PT07866632 T PT 07866632T PT 2121011 E PT2121011 E PT 2121011E
- Authority
- PT
- Portugal
- Prior art keywords
- strains
- influenza virus
- including antigen
- vaccines including
- vaccines
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87381506P | 2006-12-06 | 2006-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2121011E true PT2121011E (pt) | 2014-07-31 |
Family
ID=39492693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT78666328T PT2121011E (pt) | 2006-12-06 | 2007-12-05 | Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe |
Country Status (13)
Country | Link |
---|---|
US (3) | US20110045022A1 (pt) |
EP (3) | EP2121011B1 (pt) |
JP (1) | JP2011506264A (pt) |
CN (1) | CN101553252A (pt) |
AU (1) | AU2007330494B2 (pt) |
CA (2) | CA2671629C (pt) |
EA (1) | EA200900784A1 (pt) |
ES (1) | ES2480491T3 (pt) |
NZ (1) | NZ577405A (pt) |
PL (1) | PL2121011T3 (pt) |
PT (1) | PT2121011E (pt) |
SG (1) | SG177141A1 (pt) |
WO (1) | WO2008068631A2 (pt) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
EP2010557B1 (en) | 2006-03-31 | 2014-02-26 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
DK2066354T3 (da) | 2006-09-29 | 2013-05-27 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formuleringer |
US9474798B2 (en) | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
CN101918028B (zh) | 2007-09-18 | 2015-01-07 | 莱戈赛特医药股份有限公司 | 赋予针对诺如病毒的保护性免疫应答的疫苗 |
US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
GB0905570D0 (en) * | 2009-03-31 | 2009-05-13 | Novartis Ag | Combined vaccines |
CA2737455A1 (en) * | 2008-09-18 | 2010-03-25 | Novartis Ag | Vaccine adjuvant combinations |
KR20110132373A (ko) | 2009-02-10 | 2011-12-07 | 노파르티스 아게 | 유행병-연관 주에 대한 인플루엔자 백신 요법 |
US20120093860A1 (en) * | 2009-02-10 | 2012-04-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
CN102307590A (zh) * | 2009-02-10 | 2012-01-04 | 诺华有限公司 | 具有减少量的角鲨烯的流感疫苗 |
BRPI1011432A2 (pt) | 2009-05-08 | 2019-09-24 | Novartis Ag | ensaios genericos para deteccao de virus influenza |
EP2401384B1 (en) | 2009-05-21 | 2012-10-03 | Novartis AG | Reverse genetics using non-endogenous pol i promoters |
EP2437777B1 (en) * | 2009-06-01 | 2014-09-17 | Novartis AG | COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES |
CN102666860B (zh) | 2009-07-31 | 2015-06-17 | 诺华股份有限公司 | 反向遗传系统 |
ES2454815T3 (es) | 2009-10-20 | 2014-04-11 | Novartis Ag | Métodos mejorados de genética inversa para la recuperación de virus |
EP2493912B1 (en) | 2009-10-26 | 2020-07-29 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in vero cells |
CL2012001399A1 (es) | 2009-12-03 | 2013-03-08 | Novartis Ag | Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion. |
DE102009056884B4 (de) | 2009-12-03 | 2021-03-18 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
ES2461852T3 (es) | 2009-12-03 | 2014-05-21 | Novartis Ag | Filtración hidrófila durante la fabricación de adyuvantes para vacunas |
DE102009056883B4 (de) | 2009-12-03 | 2012-08-16 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
EP2638895B1 (en) | 2009-12-03 | 2024-03-20 | Seqirus UK Limited | Circulation of components during homogenization of emulsions |
KR101579088B1 (ko) * | 2009-12-03 | 2015-12-21 | 노파르티스 아게 | 미세 액화를 위한 상호작용 및 배압 챔버의 배치 |
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
JP6072677B2 (ja) | 2010-05-06 | 2017-02-01 | ノバルティス アーゲー | 微生物の不活化のための有機ペルオキシド化合物 |
CA2800150C (en) | 2010-05-21 | 2018-09-04 | Novartis Ag | Influenza virus reassortment method |
WO2011150264A2 (en) * | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Synthetic nanocarrier combination vaccines |
PT2575873E (pt) | 2010-06-01 | 2016-03-04 | Novartis Ag | Concentração de antigénios de vacinas com liofilização |
WO2011151723A2 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens without lyophilization |
US8302323B2 (en) * | 2010-06-21 | 2012-11-06 | Confluent Surgical, Inc. | Hemostatic patch |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9517205B2 (en) | 2010-08-20 | 2016-12-13 | Seqirus UK Limited | Soluble needle arrays for delivery of influenza vaccines |
WO2012032482A1 (en) | 2010-09-07 | 2012-03-15 | Novartis Ag | Generic assays for detection of mammalian reovirus |
CA2821992A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9821051B1 (en) | 2010-10-28 | 2017-11-21 | Seqirus UK Limited | Reducing hospitalization in elderly influenza vaccine recipients |
US20120107354A1 (en) * | 2010-10-30 | 2012-05-03 | George Dacai Liu | Viral vaccine and process for preparing the same |
EP2678452B1 (en) * | 2011-02-25 | 2016-02-24 | Novartis AG | Exogenous internal positive control for virus detection |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
BR112014000656A2 (pt) | 2011-07-11 | 2017-02-14 | Takeda Vaccines Inc | formulações de vacina parenteral contra norovírus |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
SG11201401196WA (en) | 2011-10-03 | 2014-05-29 | Moderna Therapeutics Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
EP2768528A1 (en) * | 2011-10-20 | 2014-08-27 | Novartis AG | Adjuvanted influenza b virus vaccines for pediatric priming |
SG10201604896TA (en) | 2011-12-16 | 2016-08-30 | Moderna Therapeutics Inc | Modified nucleoside, nucleotide, and nucleic acid compositions |
CA2813723A1 (en) | 2012-03-02 | 2013-09-02 | Novartis Ag | Influenza virus reassortment |
WO2013151670A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
CN102650640A (zh) * | 2012-04-24 | 2012-08-29 | 中国人民解放军第四军医大学 | 流感疫苗中的过敏原卵类粘蛋白或卵运铁蛋白定量检测 |
CA2875752A1 (en) | 2012-06-04 | 2013-12-12 | Novartis Ag | Improved safety testing |
US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
WO2014086732A2 (en) | 2012-12-03 | 2014-06-12 | Novartis Ag | Influenza virus reassortment |
CA2897752A1 (en) | 2013-01-10 | 2014-07-17 | Novartis Ag | Influenza virus immunogenic compositions and uses thereof |
MX2015011529A (es) | 2013-03-13 | 2016-02-05 | Novartis Ag | Reordenamiento del virus de infuenza b. |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
JP2016521282A (ja) | 2013-05-10 | 2016-07-21 | ノバルティス アーゲー | インフルエンザワクチンにおけるナルコレプシーのリスクの回避 |
DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
CN105722976A (zh) | 2013-06-06 | 2016-06-29 | 诺华股份有限公司 | 流感病毒重配 |
JP2016524915A (ja) | 2013-07-15 | 2016-08-22 | ウィスコンシン アルムニ リサーチ ファンデイション | Mdck、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
JP6881813B2 (ja) | 2014-04-23 | 2021-06-02 | モデルナティーエックス, インコーポレイテッド | 核酸ワクチン |
WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
RU2587629C1 (ru) * | 2014-12-29 | 2016-06-20 | Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") | Реассортантный штамм вируса гриппа rn9/13-human a(h6n9) для определения антител к нейраминидазе при гриппозной инфекции и вакцинации |
US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
RU2605317C1 (ru) * | 2015-06-04 | 2016-12-20 | Федеральное государственное автономное образовательное учреждение высшего образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) | АДАПТИРОВАННЫЕ ПАНДЕМИЧЕСКИЕ ШТАММЫ ВИРУСА ГРИППА A/Tomsk/273/2010-MA1(H1N1pdm09), A/Tomsk/273/2010-MA2(H1N1pdm09) И A/Tomsk/273/2010-MA3(H1N1pdm09) ДЛЯ ОЦЕНКИ ДЕЙСТВИЯ ПРОТИВОВИРУСНЫХ ПРЕПАРАТОВ (ВАРИАНТЫ) |
US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
WO2017062513A1 (en) | 2015-10-05 | 2017-04-13 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
US11197925B2 (en) | 2016-02-19 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Influenza B virus replication for vaccine development |
JP7336990B2 (ja) | 2017-02-27 | 2023-09-01 | フルゲン, インコーポレイテッド | インフルエンザに対する免疫原性組成物 |
GB2562241B (en) * | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
US11744801B2 (en) | 2017-08-31 | 2023-09-05 | Modernatx, Inc. | Methods of making lipid nanoparticles |
US11278612B2 (en) * | 2018-03-19 | 2022-03-22 | Novavax, Inc. | Multivalent influenza nanoparticle vaccines |
US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
WO2020167432A2 (en) | 2019-01-23 | 2020-08-20 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
MX2021010194A (es) | 2019-02-25 | 2022-01-24 | Seqirus Uk Ltd | Vacunas contra la influenza multivalentes adyuvantadas. |
US11390649B2 (en) | 2019-05-01 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
EP4061930A1 (en) | 2019-11-18 | 2022-09-28 | Seqirus Pty Ltd | Method for producing reassortant influenza viruses |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4060082A (en) | 1976-08-16 | 1977-11-29 | Mpl, Inc. | Dual-ingredient medication dispenser |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US5011828A (en) | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
GB8703696D0 (en) * | 1987-02-18 | 1987-03-25 | Oxford J S | Influenza vaccine |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
NZ241926A (en) | 1988-08-25 | 1993-08-26 | Liposome Co Inc | Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
KR970005274B1 (ko) * | 1990-08-14 | 1997-04-15 | 아이시스 파마슈티칼스, 인코포레이티드 | 안티센스 올리고뉴클레오티드에 의한 a형 인플루엔자 바이러스, 안 아아보스트레인(ann arbor strain) h2n2의 억제 |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
ES2131070T3 (es) | 1991-03-01 | 1999-07-16 | Minnesota Mining & Mfg | 1h-imidazo(4,5-c)quinolin-4-aminas sustituidas en posicion 1 y sustituidas en posicion 2. |
JPH0614756Y2 (ja) | 1991-06-26 | 1994-04-20 | 株式会社アルテ | 組み立て式の2室式容器兼用注射器 |
US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
MY111880A (en) | 1992-03-27 | 2001-02-28 | Smithkline Beecham Biologicals S A | Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a |
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
ES2143716T3 (es) | 1992-06-25 | 2000-05-16 | Smithkline Beecham Biolog | Composicion de vacuna que contiene adyuvantes. |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
DE69405551T3 (de) | 1993-03-23 | 2005-10-20 | Smithkline Beecham Biologicals S.A. | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
EP0708772B1 (en) | 1993-07-15 | 2000-08-23 | Minnesota Mining And Manufacturing Company | IMIDAZO [4,5-c]PYRIDIN-4-AMINES |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5824536A (en) * | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
US5496284A (en) | 1994-09-27 | 1996-03-05 | Waldenburg; Ottfried | Dual-chamber syringe & method |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
GB9503863D0 (en) | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
WO1998001174A1 (fr) | 1996-07-05 | 1998-01-15 | Debiotech S.A. | Seringue a chambre double permettant le melange de deux produits avant leur injection |
DE69841122D1 (de) | 1997-03-10 | 2009-10-15 | Coley Pharm Gmbh | Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
WO1999017820A1 (en) | 1997-10-03 | 1999-04-15 | Texas Pharmaceuticals, Inc. | Improved dual chamber syringe apparatus |
US5971953A (en) | 1998-01-09 | 1999-10-26 | Bachynsky; Nicholas | Dual chamber syringe apparatus |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
DE19803453A1 (de) * | 1998-01-30 | 1999-08-12 | Boehringer Ingelheim Int | Vakzine |
IL138000A0 (en) | 1998-04-09 | 2001-10-31 | Smithkline Beecham Biolog | Adjuvant compositions |
EP1075276B1 (en) | 1998-05-07 | 2007-10-17 | Corixa Corporation | Adjuvant composition and methods for its use |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
DE19835749C1 (de) | 1998-08-07 | 2000-02-03 | Dieter Perthes | Fertig-Spritze für nicht-stabile Arzneimittel |
US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
WO2000023105A2 (en) | 1998-10-16 | 2000-04-27 | Smithkline Beecham Biologicals S.A. | Adjuvant systems and vaccines |
US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
MXPA01007895A (es) | 1999-02-03 | 2003-07-21 | Biosante Pharmaceuticals Inc | Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos. |
JP4800485B2 (ja) | 1999-03-26 | 2011-10-26 | バイカル インコーポレイテッド | ポリヌクレオチドベースのワクチンに対する免疫応答を増強するためのアジュバント組成物および方法 |
WO2000060050A2 (en) | 1999-04-06 | 2000-10-12 | Wisconsin Alumni Research Foundation | Recombinant influenza viruses for vaccines and gene therapy |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
DE122007000070I1 (de) | 1999-07-14 | 2008-01-31 | Sinai School Medicine | In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren |
AR025749A1 (es) | 1999-09-24 | 2002-12-11 | Smithkline Beecham Biolog | Vacunas |
CA2383413A1 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
ATE376825T1 (de) | 1999-09-24 | 2007-11-15 | Glaxosmithkline Biolog Sa | Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung |
EP1700603A3 (en) | 1999-09-25 | 2007-06-13 | Coley Pharmaceutical GmbH | Immunostimulatory nucleic acids |
GB9923176D0 (en) * | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
US20010044416A1 (en) | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
DE60142506D1 (de) | 2000-03-03 | 2010-08-19 | Chemo Sero Therapeut Res Inst | In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle |
DE10012370A1 (de) * | 2000-03-14 | 2001-09-27 | Chiron Behring Gmbh & Co | Adjuvans für Vakzinen |
KR100848719B1 (ko) | 2000-04-28 | 2008-07-25 | 세인트 쥬드 칠드런즈 리써치 호스피탈 | 감염성 인플루엔자 바이러스 생성용 dna 트랜스펙션시스템 |
FR2808803B1 (fr) | 2000-05-11 | 2004-12-10 | Agronomique Inst Nat Rech | Cellules es modifiees et gene specifique de cellules es |
KR100877019B1 (ko) * | 2000-06-23 | 2009-01-07 | 와이어쓰 홀딩스 코포레이션 | 야생형 및 키메릭 인플루엔자 바이러스성입자(브이엘피)의 조립 |
DE60140456D1 (de) | 2000-09-01 | 2009-12-24 | Novartis Vaccines & Diagnostic | Aza heterocyclische derivate und ihre therapeutische verwendung |
CA2421120C (en) | 2000-09-11 | 2008-07-15 | Chiron Corporation | Quinolinone derivatives as tyrosine kinase inhibitors |
ES2298269T3 (es) | 2000-09-26 | 2008-05-16 | Idera Pharmaceuticals, Inc. | Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales. |
GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US6660747B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
EP2281573A3 (en) | 2001-02-23 | 2011-12-07 | GlaxoSmithKline Biologicals s.a. | Influenza vaccine formulations for intradermal delivery |
AR032575A1 (es) | 2001-02-23 | 2003-11-12 | Smithkline Beecham Biolog | Uso de una preparacion antigenica de gripe para la fabricacion de una vacuna intradermica de la gripe y estuche farmaceutico que comprende dicha vacuna |
WO2002072012A2 (en) | 2001-03-09 | 2002-09-19 | Id Biomedical Corporation Of Quebec | A novel proteosome-liposaccharide vaccine adjuvant |
TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
FR2832423B1 (fr) | 2001-11-22 | 2004-10-08 | Vivalis | Systeme d'expression de proteines exogenes dans un systeme aviaire |
NZ533628A (en) | 2001-11-27 | 2006-07-28 | Anadys Pharmaceuticals Inc | 3-beta-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and uses thereof |
US7321033B2 (en) | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
PT1499311E (pt) | 2002-03-29 | 2010-03-10 | Novartis Vaccines & Diagnostic | Benzazois substituídos e sua utilização como inibidores da raf cinase |
WO2003101949A2 (en) | 2002-05-29 | 2003-12-11 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
US20060147477A1 (en) * | 2002-06-11 | 2006-07-06 | Glaxo Group Limited | Immunogenic compositions |
AU2003251518B2 (en) | 2002-06-13 | 2009-07-02 | New York University | Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
KR20050038631A (ko) | 2002-08-23 | 2005-04-27 | 카이론 코포레이션 | 글리코겐 신타제 키나제 3의 피롤 기제 억제제 |
AU2003300021A1 (en) | 2002-12-27 | 2004-07-29 | Chiron Corporation | Thiosemicarbazones as anti-virals and immunopotentiators |
EP1594524B1 (en) | 2003-01-21 | 2012-08-15 | Novartis Vaccines and Diagnostics, Inc. | Use of tryptanthrin compounds for immune potentiation |
GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
WO2004080403A2 (en) * | 2003-03-07 | 2004-09-23 | Merck & Co. Inc. | Influenza virus vaccine |
CA2517673C (en) * | 2003-03-24 | 2013-08-13 | Intercell Ag | Improved vaccines for preventing viral infection |
EP1608369B1 (en) | 2003-03-28 | 2013-06-26 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
RU2236257C1 (ru) | 2003-09-15 | 2004-09-20 | Косяков Константин Сергеевич | Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами |
US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
KR101153898B1 (ko) | 2004-03-23 | 2012-06-18 | 니프로 가부시키가이샤 | 프리필드 시린지 |
CA2560969A1 (en) | 2004-03-31 | 2005-11-03 | New York University | Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases |
EP2269644A3 (en) | 2004-04-05 | 2012-10-17 | Pfizer Products Inc. | Microfluidized oil-in-water emulsions and vaccine compositions |
WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
RU2006145303A (ru) | 2004-05-20 | 2008-06-27 | АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН (CA) | Способ получения противогриппозной вакцины |
JP2008504292A (ja) | 2004-06-24 | 2008-02-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | 免疫増強用の化合物 |
DE602005024827D1 (de) | 2004-09-09 | 2010-12-30 | Novartis Vaccines & Diagnostic | Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen |
CA2592120A1 (en) | 2004-12-23 | 2006-07-06 | Medimmune Vaccines, Inc. | Non-tumorigenic mdck cell line for propagating viruses |
NZ556061A (en) | 2004-12-24 | 2009-06-26 | Solvay Biologicals Bv | Rescue of influenza virus |
EP1851314A2 (en) * | 2005-02-24 | 2007-11-07 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
KR20160064249A (ko) * | 2005-03-23 | 2016-06-07 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Cd4 t-세포 및/또는 개선된 b-메모리 세포 반응을 유도하는 인플루엔자 바이러스 및 수중유 에멀젼 애주번트의 용도 |
FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
CA2646349A1 (en) * | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
US20100010199A1 (en) * | 2006-09-11 | 2010-01-14 | Novartis Ag | Making influenza virus vaccines without using eggs |
US20120093860A1 (en) * | 2009-02-10 | 2012-04-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
AU2011225748A1 (en) * | 2010-03-08 | 2012-09-13 | Novartis Ag | Methods of testing for intracellular pathogens |
-
2007
- 2007-12-05 CA CA2671629A patent/CA2671629C/en active Active
- 2007-12-05 PL PL07866632T patent/PL2121011T3/pl unknown
- 2007-12-05 PT PT78666328T patent/PT2121011E/pt unknown
- 2007-12-05 WO PCT/IB2007/004364 patent/WO2008068631A2/en active Application Filing
- 2007-12-05 CN CNA2007800452261A patent/CN101553252A/zh active Pending
- 2007-12-05 EP EP07866632.8A patent/EP2121011B1/en not_active Revoked
- 2007-12-05 EP EP12180148A patent/EP2532362A1/en not_active Ceased
- 2007-12-05 ES ES07866632.8T patent/ES2480491T3/es active Active
- 2007-12-05 SG SG2011088036A patent/SG177141A1/en unknown
- 2007-12-05 NZ NZ577405A patent/NZ577405A/xx not_active IP Right Cessation
- 2007-12-05 CA CA2976230A patent/CA2976230A1/en not_active Abandoned
- 2007-12-05 EP EP13185690.8A patent/EP2679240A1/en not_active Withdrawn
- 2007-12-05 EA EA200900784A patent/EA200900784A1/ru unknown
- 2007-12-05 JP JP2009539832A patent/JP2011506264A/ja active Pending
- 2007-12-05 US US12/448,057 patent/US20110045022A1/en not_active Abandoned
- 2007-12-05 AU AU2007330494A patent/AU2007330494B2/en active Active
-
2013
- 2013-09-24 US US14/035,668 patent/US20140178429A1/en not_active Abandoned
-
2018
- 2018-11-30 US US16/205,682 patent/US20190314483A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2679240A1 (en) | 2014-01-01 |
EP2532362A1 (en) | 2012-12-12 |
WO2008068631A2 (en) | 2008-06-12 |
EA200900784A1 (ru) | 2009-12-30 |
JP2011506264A (ja) | 2011-03-03 |
EP2121011A2 (en) | 2009-11-25 |
CA2976230A1 (en) | 2008-06-12 |
US20110045022A1 (en) | 2011-02-24 |
EP2121011B1 (en) | 2014-05-21 |
CA2671629C (en) | 2017-08-15 |
AU2007330494B2 (en) | 2014-03-13 |
CN101553252A (zh) | 2009-10-07 |
AU2007330494A1 (en) | 2008-06-12 |
US20190314483A1 (en) | 2019-10-17 |
ES2480491T3 (es) | 2014-07-28 |
US20140178429A1 (en) | 2014-06-26 |
WO2008068631A8 (en) | 2009-07-23 |
NZ577405A (en) | 2012-08-31 |
CA2671629A1 (en) | 2008-06-12 |
WO2008068631A3 (en) | 2008-11-13 |
PL2121011T3 (pl) | 2014-10-31 |
SG177141A1 (en) | 2012-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2121011T3 (pl) | Szczepionki zawierające antygeny czterech szczepów wirusa grypy | |
IL186611A0 (en) | Vaccine against pandemic strains of influenza viruses | |
EP2217064A4 (en) | NEW VACCINES AGAINST SEVERAL SUBTYPES OF THE INFLUENZAVIRUS | |
EP1984405A4 (en) | INFLUENZA ANTIGENS, VACCINE COMPOSITIONS AND ASSOCIATED METHODS | |
ZA201004478B (en) | Antibodies against influenza virus and methods of use thereof | |
IL203869A (en) | Method of Preparing a Containing a Virus or Antigen Antigen, Various Aspects Related to This Method, Uses of a Method and Vaccination of a Split Virus Prepared by This Method | |
EP2091960A4 (en) | PEPTIDE VACCINE AGAINST INFLUENZA VIRUS | |
IL210451A (en) | Epitope for influenza virus vaccine | |
EP2552479A4 (en) | INFLUENZA VIRUS VACCINES AND USES THEREOF | |
EP2118323A4 (en) | DETECTION OF INFLUENZA VIRUS | |
EP1948227A4 (en) | COMBINATORY ANTIGEN VACCINE AGAINST FLU | |
IL196024A0 (en) | Influenza vaccine | |
EP2380976A4 (en) | HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS | |
EP1970707A4 (en) | METHOD FOR DETECTION OF A VIRULENT STRAIN OF THE INFLUENZA VIRUS | |
SI2422810T1 (sl) | Influenčno cepivo | |
ZA200809056B (en) | Influenza virus vaccine | |
IL214385A (en) | Inactive dengue virus vaccine with aluminum-free assists | |
GB0900772D0 (en) | Live vaccine strains of francisella | |
EP1957101A4 (en) | DSRNA AS INFLUENZA VIRUS IMPFSTOFF ADJUVANTIES OR IMMUNOSTIMULATORS | |
EP1998814A4 (en) | NEW VACCINES AGAINST INFLUENZA M2 | |
HUE051711T2 (hu) | Influenzavakcina antigénjeinek koncentrálása liofilizálás nélkül | |
EP1871786A4 (en) | PEPTIDE VACCINE AGAINST THE GRIPPEVIRUS | |
ZA201008125B (en) | Inactivated live-attenuated bluetongue virus vaccine | |
EP2327714A4 (en) | PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST FLUID VIRUS INFECTION | |
EP2195019A4 (en) | METHOD FOR TRIGGERING AN IMMUNE RESPONSE AGAINST THE PANDEMIC INFLUENZA VIRUS |